The cancer immunotherapy blog

19 Feb In vitro immune cell activation

We set up a specialized in vitro immune cell activation assay based on the high throughput HTRF quantitation of key cytokine (e.g. IFNg) release, to assess your candidate compounds and biologics, as single agents and/or in combination, for their immunomodulatory properties to enhance immune cell...

Read More

31 May In vitro immune cell-mediated killing

In vitro immune cell killing assay to assess your immunomodulatory candidate compounds/antibodies for their ability to enhance the killing immune response towards tumor cells. By using live cell imaging platform, our sensitive and quantitative assay based on 96-well plate co-culture of human tumor cells...

Read More

14 Feb Orthotopic mouse model of Glioblastoma

Glioblastoma (GBM) is the most aggressive primary brain tumor. Despite multimodal treatment strategies with surgery, radiation therapy and chemotherapy, the prognosis of GBM patients remains dismal. GBM are characterized by a high immune cells infiltration including myeloid derived suppressor cells (MDSCs), microglia or regulatory T...

Read More